Study to Examine the Effect of Coated Phenylephrine Suppositories on Anal Pressure in Healthy Subjects
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is an open label, dose-finding study. Approximately 8 healthy subjects will be participating in this study.
A screening will be used to determine subject suitability for inclusion in the trial. Subjects who meet all inclusion criteria and none of the exclusion criteria will enter a one day treatment period. During this period, 4 anal manometric studies will take place. Study medication (Coated Phenylephrine suppositories at various doses) will be administered at pre-determined intervals.
| Condition | Intervention | Phase |
|---|---|---|
|
Incontinence |
Drug: Phenyephrine |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label |
| Official Title: | An Open Label Study to Examine the Effect of Coated Phenylephrine Suppositories on Anal Pressure in Healthy Subjects |
- The primary efficacy parameter is change in Resting Anal Pressure from baseline. [ Time Frame: 8 hours ] [ Designated as safety issue: No ]
- The ratio of change in anal pressure to plasma Phenylephrine level. [ Time Frame: 8 hours ] [ Designated as safety issue: Yes ]
- The ratio of change in anal pressure to change in blood pressure. [ Time Frame: 8 hours ] [ Designated as safety issue: Yes ]
- The ratio of change in anal pressure to change in heart rate. [ Time Frame: 8 hours ] [ Designated as safety issue: Yes ]
| Enrollment: | 8 |
| Study Start Date: | September 2009 |
| Study Completion Date: | December 2009 |
| Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Healthy individuals |
Drug: Phenyephrine
Phenyephrine coated suppositories
|
Detailed Description:
This is an open label, dose-finding study. Approximately 8 healthy subjects will be participating in this study. A screening will be used to determine subject suitability for inclusion in the trial. Within one week after the screening visit, subjects who meet all inclusion criteria and none of the exclusion criteria will enter a one day treatment period. During this period, 4 anal manometric studies will take place. Study medication (Coated Phenylephrine suppositories at various doses) will be administered at pre-determined intervals. During the study, blood samples will be obtained for plasma Phenylephrine analysis.After determining baseline resting anal pressure with a manometric test, coated Suppositories will be administered intra rectally. Subjects will take rectally a total of 1 Coated Suppository per study. 60, 120 and 240 minutes after the coated suppository insertion amnometric studies will be performed: The first 2 subjects in the study will receive 40 mg phenyephrine coated suppositories. If significant (> 15%) increase in the resting anal pressure will occur with this dose, the rest of the study subjects will receive the same dose. If the raise in the resting anal pressure will not be significant AND no adverse events was observed, than the following subjects will receive 80 mg phenylehprine coated suppositories.
Eligibility| Ages Eligible for Study: | 18 Years to 55 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Signed written informed consent.
- Male or female subjects 18 to 55 years of age.
Exclusion Criteria:
- Active or chronic disease.
- In need of chronic use of medication, with the exception of birth control medications.
- Currently uses medication for acute illness.
- Has used, in the last four weeks, drugs that may affect blood coagulation, such as Aspirin, Warfarin, Sintrom, Enoxaparin, Nadroparin, Heparin, Clopidogrel, Ticlopidine.
- Has upon physical examination a rectal deformation or signs of rectal disease such as fissure, bleeding hemorrhoids, fistula., infection or space occupying lesion.
- Receipt of any investigational treatment (drug or device) within 90 days prior to screening.
Contacts and Locations| Israel | |
| Dept of Gastroeneterology, Asaf Harofe Medical Center | |
| Zrifin, Israel, 70300 | |
| Principal Investigator: | Shlomo Shapiro, MD | Dept of gastroeneterology, asaf harofe medical center |
More Information
No publications provided
| Responsible Party: | Michael Shapiro MD, Gastroenterology Dept, Asaf Harofe Medical Center |
| ClinicalTrials.gov Identifier: | NCT00972998 History of Changes |
| Other Study ID Numbers: | RDD 105 |
| Study First Received: | August 17, 2009 |
| Last Updated: | December 28, 2009 |
| Health Authority: | Israel: Ethics Commission |
Keywords provided by RDD Pharma Ltd:
|
anal sphincter pressure phenyephrine |
Additional relevant MeSH terms:
|
Phenylephrine Oxymetazoline Adrenergic alpha-1 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Physiological Effects of Drugs Cardiotonic Agents |
Cardiovascular Agents Therapeutic Uses Mydriatics Autonomic Agents Peripheral Nervous System Agents Sympathomimetics Vasoconstrictor Agents Nasal Decongestants Respiratory System Agents Protective Agents |
ClinicalTrials.gov processed this record on May 16, 2013